Hannah Scheiblich

Hannah Scheiblich is a Max Planck Research Group Leader at the Max Planck Institute for Biology of Ageing (Cologne, Germany) since 2024. Her work focuses on the neuroimmunology of aging, particularly the role of microglia in neurodegenerative diseases like Alzheimer's and Parkinson's. She investigates how microglial dysfunction contributes to chronic inflammation and pathology.

• PhD in Natural Sciences (Dr. rer. nat., 2015, University of Veterinary Medicine Hannover)
• Master of Science (MSc, 2011, University of Veterinary Medicine Hannover)
• Bachelor of Science (BSc, 2009, Philipps-University of Marburg)

Her research spans three key areas:

• Mechanisms of microglial phagocytosis and intercellular cargo transfer via tunneling nanotubes
• Role of NLRP3 inflammasome activation in neurodegeneration
• Regulation of microglial migration and function through signaling pathways like NO/cGMP and HO-1/CO

Publications highlight her work on:

• α-synuclein degradation strategies
• Tau pathology in Alzheimer's disease
• Neuroinflammatory signaling in prion diseases
• Cross-talk between neurons and microglia
• Alcohol-induced microglial dysfunction

Scientific awards include:

• Best Poster Prize (2023, 7th Venusberg Meeting)
• 3rd place Best Paper Prize (2022, German Center for Neurodegenerative Diseases)
• Mark A. Smith Prize (2017, Journal of Neurochemistry)

She has received funding from:

• Alzheimer Forschung Initiative (2024-2027)
• Gemeinnützige Hertie Stiftung (2020-2023)
• Cluster of Excellence ImmunoSensation (2023)